Phase III Clinical Study of JTE-052 Ointment - Randomized Controlled and Long-Term Extension Study of JTE-052 Ointment in Japanese Pediatric Patients with Atopic Dermatitis

Following dermal application of JTE-052 ointment 0.25% twice daily for 4 weeks in pediatric patients with AD, the percent improvement in mEASI score at EOT was significantly greater in the 0.25% group than in the placebo group, demonstrating the superiority of the 0.25% group over the placebo group. Twice-daily application of JTE-052 ointment 0.25% or 0.5% for up to 56 weeks was safe and well tolerated in pediatric patients with AD. The improvements in AD were maintained during the treatment period.